NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, December 13th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.36 per share on Friday, February 14th. This represents a $1.44 annualized dividend and a dividend yield of 1.67%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.32. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday, October, 16th. The healthcare product maker reported $0.84 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.84. The healthcare product maker earned $8.08 billion during the quarter, compared to analysts' expectations of $8.10 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 10.50%. The company's revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.75 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories updated its FY19 earnings guidance on Wednesday, October, 16th. The company provided EPS guidance of $3.23-3.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.24.

15 analysts have issued 1-year target prices for Abbott Laboratories' shares. Their forecasts range from $68.00 to $98.00. On average, they expect Abbott Laboratories' stock price to reach $88.67 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Headlines about ABT stock have trended neutral this week, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Abbott Laboratories.

Abbott Laboratories saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 18,860,000 shares, an increase of 7.8% from the November 14th total of 17,500,000 shares. Based on an average trading volume of 4,570,000 shares, the days-to-cover ratio is presently 4.1 days. Currently, 1.1% of the shares of the company are short sold. View Abbott Laboratories' Current Options Chain.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Pfizer (PFE), NVIDIA (NVDA), Home Depot (HD), Intel (INTC), Micron Technology (MU) and Walt Disney (DIS).

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.10%), Massachusetts Financial Services Co. MA (1.80%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Parametric Portfolio Associates LLC (0.38%), Diamond Hill Capital Management Inc. (0.36%) and California Public Employees Retirement System (0.23%). Company insiders that own Abbott Laboratories stock include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Coho Partners Ltd., Massachusetts Financial Services Co. MA, Columbus Circle Investors, Sawgrass Asset Management LLC, Montag & Caldwell LLC, Sector Gamma AS and State of New Jersey Common Pension Fund D. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Assenagon Asset Management S.A., State of Tennessee Treasury Department, Bartlett & Co. LLC, Voloridge Investment Management LLC, State of Alaska Department of Revenue and Banco Santander S.A.. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $86.35.

Abbott Laboratories has a market capitalization of $152.71 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.